Skip to main content

Dr. Senthilkumar Damodaran, M.D. PH.D.

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
25
In the NPI registry since
2008
Medicare patients seen, 2024
115

Licensed in Texas since 2015, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    TX license Q5786 (first issued 2015; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
115
Services billed
307
Patients’ average age
72
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes11649
Established patient office or other outpatient visit, 30-39 minutes10459
New patient office or other outpatient visit, 60-74 minutes2222

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Letrozole
Other prescribers in Houston, TX
198
Anastrozole
Other prescribers in Houston, TX
51
Verzenio (abemaciclib)39
Ondansetron Hcl
Other prescribers in Houston, TX
27
Ibrance (palbociclib)24
Exemestane16
Prochlorperazine Maleate
Other prescribers in Houston, TX
16
Kisqali (ribociclib succinate)16
Everolimus14
Tamoxifen Citrate
Other prescribers in Houston, TX
11

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 2 companies reported 16 payments worth $11,511 in total to this clinician.

By type
Consulting Fee$9,128
Travel and Lodging$2,210
Food and Beverage$173

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Mar 12, 2025AstraZeneca UK Limited
Mar 12, 2025
Consulting Fee
Company’s descriptionResearch Related Service
$3,853
May 12, 2025Eli Lilly and Company
May 12, 2025
Consulting Fee
Company’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES
$2,400
Jul 29, 2025AstraZeneca UK Limited
Jul 29, 2025
Consulting Fee$1,675
Sep 25, 2025Eli Lilly and Company
Sep 25, 2025
Consulting Fee
Company’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES
$1,200
Apr 28, 2025Eli Lilly and Company
Apr 28, 2025
Travel and Lodging
travel to NEW YORK CITY, TX · in-kind
$958
Apr 28, 2025Eli Lilly and Company
Apr 28, 2025
Travel and Lodging
travel to NEW YORK CITY, NY · in-kind
$347
Apr 28, 2025Eli Lilly and Company
Apr 28, 2025
Travel and Lodging
travel to NEW YORK CITY, NY · in-kind
Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS
$278
Apr 28, 2025Eli Lilly and Company
Apr 28, 2025
Travel and Lodging
travel to NEW YORK CITY, NY · in-kind
Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS
$274
Apr 28, 2025Eli Lilly and Company
Apr 28, 2025
Travel and Lodging
travel to NEW YORK CITY, NY · in-kind
Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS
$257
May 16, 2025Eli Lilly and Company
May 16, 2025
Travel and Lodging
travel to NEW YORK, NY
Company’s descriptionTRAVEL EXPENSES RELATED TO PROVIDING RESEARCH RELATED SERVICES
$95.42

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $2,711,423 in research payments for these studies, mostly to the institutions running them.

  • Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
    Daiichi Sankyo Inc. · Active, not recruiting · NCT05633979
  • A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurren…
    AstraZeneca Pharmaceuticals LP
  • A Phase I/II, open label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth re…
    Novartis Pharmaceuticals Corporation
  • A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in combination with ribocilcib and fulvestrant in subjects participants withER-positive, HER2- negative and GRPR-positive breast cancer, ex…
    Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Houston

Sources

NPI registry (CMS NPPES, November 2026; record last updated December 14, 2015), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1174786636. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.